Breakthrough trial aims to free kidney transplant patients from lifelong medications
NCT ID NCT04803058
First seen Feb 06, 2026 · Last updated Apr 16, 2026 · Updated 6 times
Summary
This study is testing whether a drug called TCD601 (Siplizumab), combined with donor bone marrow cells and mild chemotherapy, can help kidney transplant recipients safely reduce or stop their lifelong anti-rejection medications. The goal is to help the body accept the new kidney without needing constant immune-suppressing drugs. Researchers are enrolling 18 adult patients who received a kidney from a living donor to test the safety and effectiveness of this approach.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for KIDNEY TRANSPLANTATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
Mayo Clinic
Rochester, Minnesota, 55905, United States
-
Samsung Medical University
Seoul, South Korea
Conditions
Explore the condition pages connected to this study.